New Rochelle, NY, November 29, 2012--Osteoporosis, or reduced bone mineral density that can increase the risk of fractures, may affect as many as 30% of women and 12% of men worldwide. One risk factor for osteoporosis is vitamin D deficiency. A modified form of the vitamin D receptor present in some individuals may lower their risk for developing osteoporosis, according to an article in Genetic Testing and Molecular Biomarkers, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Genetic Testing and Molecular Biomarkers website.
To act on cells in the body, vitamin D binds to a specific receptor on the surface of cells. A variation in the gene for the vitamin D receptor (called the Bsm I polymorphism) may change this interaction. In the article, "Vitamin D Receptor BSM I Polymorphism and Osteoporosis Risk: A Meta-Analysis from 26 Studies," authors Fu Jia and colleagues, Kunming Medical University and Yunnan University of Chinese Traditional Medicine, Yunnan, People's Republic of China, report that people with this genetic variation appear to have a significantly decreased risk of developing osteoporosis.
"This meta-analysis provides a pathway to help determine the likelihood that a person may develop osteoporosis and is a good example for the potential application of genetics to clinical medicine," says Kenneth I. Berns, MD, PhD, Editor-in-Chief of Genetic Testing and Molecular Biomarkers, and Director of the University of Florida's Genetics Institute, College of Medicine, Gainesville, FL.
About the Journal
Genetic Testing and Molecular Biomarkers is an authoritative peer-reviewed journal published 12 times per year in print and online that reports on all aspects of genetic testing, including molecular and biochemical based tests and varied clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. Tables of content and a free sample issue may be viewed on the Genetic Testing and Molecular Biomarkers website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy and OMICS: A Journal of Integrative Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc.
140 Huguenot St.,
New Rochelle, NY 10801-5215
Phone: 914-740-2100 800-M-LIEBERT Fax: 914-740-2101 www.liebertpub.com